The precision genomic medicine landscape has evolved dramatically from early double-strand break (DSB) technologies to ultra-precise single-nucleotide base editors and prime editing systems. This review details clinical trial milestones and molecular safety frameworks.
In Vivo vs. Ex Vivo Delivery Paradigms
Gene editing therapies in active clinical phases are deployed through two distinct modalities:
- Ex Vivo Autologous Cellular Editing: Patient hematopoietic stem and progenitor cells (HSPCs) are harvested, edited via electroporated Cas9 ribonucleoprotein (RNP) complexes, and re-infused following myeloablative conditioning (e.g., Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia).
- In Vivo Lipid Nanoparticle (LNP) Delivery: Synthetic mRNA encoding Cas9/base editor along with chemically modified guide RNA (sgRNA) are encapsulated in liver-tropic LNPs targeting hepatic genes such as PCSK9 and TTR (transthyretin amyloidosis).
ā” Molecular Safety: Off-Target Interception
High-throughput genome-wide sequencing protocols (such as GUIDE-seq and CIRCLE-seq) have demonstrated <0.01% off-target cleavage when employing high-fidelity Cas enzymes (e.g., HiFi Cas9, SpG variants).
Base Editing: Correcting Point Mutations Without DSBs
Cytosine Base Editors (CBEs) and Adenine Base Editors (ABEs) tether a catalytically impaired Cas9 nickase to a deaminase domain, executing targeted CāT or AāG transitions without inducing toxic double-strand breaks or large chromosomal rearrangements.